Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Br J Haematol. 2011 Sep 9;155(3):340–348. doi: 10.1111/j.1365-2141.2011.08849.x

Table 3.

Best Overall Response by Treatment

RD: Prop [freq/n] (95%CI) Rd: Prop [freq/n] (95%CI) Abs. Diff. (95%CI) Odds Ratio (95%CI)
≥ Very Good Partial Response
Overall Cohort 50.5% [108/214] (43.8%,57.2%) 40.4% [84/208] (33.7%,47.1%) 10.1% (0.6%,19.5%) 1.50 (1.02,2.21)
High Risk 36.4% [4/11] (7.9%,64.8%) 22.2% [2/9] (0.0%,49.4%) 14.1% (−25.2%,53.5%) 2.00 (0.27,14.70)
Standard Risk 50.0% [23/46] (35.6%,64.4%) 43.1% [25/58] (30.4%,55.8%) 6.9% (−12.4%,26.2%) 1.32 (0.61,2.87)
≥ Partial Response
Overall Cohort 81.3% [174/214] (76.1%,86.5%) 70.2% [146/208] (64.0%,76.4%) 11.1% (3.0%,19.2%) 1.85 (1.17,2.91)
High Risk 72.7% [8/11] (46.4%,99.0%) 77.8% [7/9] (50.6%,100.0%) −5.1% (−42.9%,32.8%) 0.76 (0.10,5.96)
Standard Risk 82.6% [38/46] (71.7%,93.6%) 72.4% [42/58] (60.9%,83.9%) 10.2% (−5.7%,26.1%) 1.81 (0.70,4.70)